PC945

Research use only, not for human use.

PC945 is a novel broad spectrum antifungal agent that potently inhibits Aspergillus fumigatus sterol 14α-demethylase (CYP51A and CYP51B) with IC50 of 0.23 and 0.22 uM, respectively.

PC945 is a novel broad spectrum antifungal agent that potently inhibits Aspergillus fumigatus sterol 14α-demethylase (CYP51A and CYP51B) with IC50 of 0.23 and 0.22 uM, respectively; shows MIC values 0.032 to >8 ug/ml against 96 clinically isolated A. fumigatus strains, demonstrates activity against itraconazole-susceptible and -resistant A. fumigatus growth with IC50 of 0.0012 to 0.034 ug/ml; PC945 is a broad spectrum of pathogenic fungi with MIC 0.0078 to 2 ug/ml, and exhibits activity in vivo.Fungal Infection Phase 1 Clinical.

PC945 is a triazole antifungal designed for administration via inhalation.PC945 exhibits the most potent antifungal activity on azole-susceptible strain NCPF2010 with the MIC value of 0.063?μg/mL.

PC945 (0.56-14 μg/mouse; intranasal; daily for 7 days) substantially inhibits the incidence of rolling behavior. Animal Model:Specific-pathogen-free A/J mice (male, 5 weeks old, pulmonary Aspergillus infection)Dosage:0.56, 2.8, 14 μg/mouse (intranasal application of 0.016-, 0.08-, and 0.4-mg/ml suspensions, respectively)Administration:Intranasal; daily for 7 days Result:Substantially inhibited the incidence of rolling behavior.

PC 945

Microbiology/Virology

Fungal

Fungal

Infection

Fungal Infection

1931946-73-4

682.748

C38H37F3N6O3

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (146.47 mM)

——

4-[4-(4-{[(3R,5R)-5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy}-3-methylphenyl)piperazin-1-yl]-N-(4-fluorophenyl)benzamide

(-20℃)

With Ice Pack

≥ 2 years